All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

What to do during Bacillus Calmette-Guerin shortage? Valid strategies based on evidence

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10387170" target="_blank" >RIV/00216208:11130/18:10387170 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064203:_____/18:10387170

  • Result on the web

    <a href="https://doi.org/10.1097/MOU.0000000000000544" target="_blank" >https://doi.org/10.1097/MOU.0000000000000544</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1097/MOU.0000000000000544" target="_blank" >10.1097/MOU.0000000000000544</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    What to do during Bacillus Calmette-Guerin shortage? Valid strategies based on evidence

  • Original language description

    Purpose of review Over the last decade, the world has experienced health-threatening supply shortages of Bacillus Calmette-Guerin (BCG) immunotherapy for nonmuscle-invasive bladder cancer (NMIBC). We summarize the current literature to assist in treatment decisions in light of suboptimal supply. Recent findings Currently available data do not support a superiority of one BCG strain over the other. Intravesical chemotherapy seems to provide similar results in term of disease progression but not recurrence in intermediate-risk patients. One trial has shown that a 3-year maintenance course of BCG in high-risk NMIBC has no advantage in term of progression or overall survival in comparison with 1-year maintenance. Synergo radiofrequency-induced hyperthermia is a reliable alternative in intermediate or high-risk NMIBC with at least similar recurrence rates compared with BCG. Summary Patients with intermediate-risk NMIBC can be offered multiple instillations of intravesical chemotherapy for up to 12 months. In high-risk patients and in case of BCG shortage, BCG instillations can be terminated when the patient has completed 1 year of maintenance. Mitomycin C is an alternative in lowest risk high-risk (G3Ta) NMIBC, whereas patients with pT1/carcinoma in situ can be offered Synergo with mitomycin C when radical cystectomy is not feasible. Immediate radical cystectomy should always be considered in highest risk NMIBC after weighing up benefit to risk.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30217 - Urology and nephrology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Current Opinion in Urology

  • ISSN

    0963-0643

  • e-ISSN

  • Volume of the periodical

    28

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    7

  • Pages from-to

    570-576

  • UT code for WoS article

    000452678200015

  • EID of the result in the Scopus database

    2-s2.0-85064210938